Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

por Plummer, Ruth
Publicado 2011

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors

por Plummer, Ruth, Stephens, Peter, Aissat-Daudigny, Louiza, Cambois, Anne, Moachon, Gilbert, Brown, Peter D., Campone, Mario
Publicado 2014

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

por Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Publicado 2020

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours:...

por Cranston, Amy, Stocken, Deborah D., Stamp, Elaine, Roblin, David, Hamlin, Julia, Langtry, James, Plummer, Ruth, Ashworth, Alan, Burn, John, Rajan, Neil
Publicado 2017

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

por Brown, Jennifer, Plummer, Ruth, Bauer, Todd M., Anthony, Stephen, Sarantopoulos, John, De Vos, Filip, White, Mike, Schupp, Marco, Ou, Ying, Vaishampayan, Ulka
Publicado 2017

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

por Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.
Publicado 2021

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

por Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth
Publicado 2021

Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations

por Williams, Kristian C., Gault, Abigail, Anderson, Amy E., Stewart, Christopher J., Lamb, Christopher A., Speight, R. Ally, Rajan, Neil, Plummer, Ruth, Pratt, Arthur G.
Publicado 2023

Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer

por Shaheen, Fadhel S., Znojek, Pawel, Fisher, Ann, Webster, Martin, Plummer, Ruth, Gaughan, Luke, Smith, Graeme C. M., Leung, Hing Y., Curtin, Nicola J., Robson, Craig N.
Publicado 2011

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

por Plummer, Ruth, Madi, Ayman, Jeffels, Melinda, Richly, Heike, Nokay, Bahar, Rubin, Stephen, Ball, Howard A., Weller, Steve, Botbyl, Jeffrey, Gibson, Diana M., Scheulen, Max E.
Publicado 2012

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965

por McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Publicado 2020

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965

por McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Publicado 2020

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto...

por Menne, Tobias, Slade, Daniel, Savage, Joshua, Johnson, Sarah, Irving, Julie, Kearns, Pamela, Plummer, Ruth, Shenton, Geoff, Veal, Gareth J, Vormoor, Britta, Vormoor, Josef, Billingham, Lucinda
Publicado 2022

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

por Twelves, Chris, Anthoney, Alan, Savulsky, Claudio I., Guo, Matthew, Reyderman, Larisa, Cresti, Nicola, Semiglazov, Vladimir, Timcheva, Constanta, Zubairi, Ishtiaq, Morrison, Rosemary, Plummer, Ruth, Evans, T. R. Jeffry
Publicado 2019

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

por Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Publicado 2017

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

por Yap, Timothy A, Siu, Lillian L, Calvo, Emiliano, Lolkema, Martijn P, LoRusso, Patricia M, Soria, Jean-Charles, Plummer, Ruth, de Bono, Johann S, Tabernero, Josep, Banerji, Udai
Publicado 2021

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

por Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis
Publicado 2020

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

por Sanborn, Rachel E, Hamid, Omid, de Vries, Elisabeth GE, Ott, Patrick A, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A, Cho, Daniel C, Plummer, Ruth, Stroh, Mark, Lu, Lawrence, Thistlethwaite, Fiona
Publicado 2021

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

por Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Publicado 2023

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

por Jones, Robert, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S., Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Publicado 2023